- Home
- TXO vs NRIX Comparison
TXO vs NRIX Comparison
Compare TXO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXO
- NRIX
- Stock Information
- Founded
- TXO 2012
- NRIX 2009
- Country
- TXO United States
- NRIX United States
- Employees
- TXO N/A
- NRIX N/A
- Industry
- TXO Oil & Gas Production
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- TXO Energy
- NRIX Health Care
- Exchange
- TXO Nasdaq
- NRIX Nasdaq
- Market Cap
- TXO 788.9M
- NRIX 728.6M
- IPO Year
- TXO 2023
- NRIX 2020
- Fundamental
- Price
- TXO $14.10
- NRIX $9.41
- Analyst Decision
- TXO Strong Buy
- NRIX Strong Buy
- Analyst Count
- TXO 2
- NRIX 15
- Target Price
- TXO $22.50
- NRIX $29.13
- AVG Volume (30 Days)
- TXO 206.4K
- NRIX 592.9K
- Earning Date
- TXO 08-05-2025
- NRIX 10-10-2025
- Dividend Yield
- TXO 17.15%
- NRIX N/A
- EPS Growth
- TXO N/A
- NRIX N/A
- EPS
- TXO 0.30
- NRIX N/A
- Revenue
- TXO $332,267,000.00
- NRIX $88,381,000.00
- Revenue This Year
- TXO $31.08
- NRIX $74.59
- Revenue Next Year
- TXO $11.32
- NRIX N/A
- P/E Ratio
- TXO $47.26
- NRIX N/A
- Revenue Growth
- TXO 15.94
- NRIX 41.86
- 52 Week Low
- TXO $13.35
- NRIX $8.18
- 52 Week High
- TXO $20.70
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- TXO 41.81
- NRIX 35.98
- Support Level
- TXO $13.85
- NRIX $9.28
- Resistance Level
- TXO $14.15
- NRIX $10.33
- Average True Range (ATR)
- TXO 0.33
- NRIX 0.54
- MACD
- TXO 0.01
- NRIX -0.03
- Stochastic Oscillator
- TXO 50.34
- NRIX 7.65
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.